Overview

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Status:
Completed

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory Acute Lymphoblastic Leukemia (ALL) and to assess whether this dose of blinatumomab is effective.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Amgen Research (Munich) GmbH

Treatments:

Antibodies, Bispecific
Blinatumomab